United Therapeutics Corporation $UTHR Shares Bought by Galvin Gaustad & Stein LLC

Key Points

• Galvin Gaustad & Stein LLC increased its stake in United Therapeutics by 21.6%, now holding 37,086 shares valued at approximately $10.66 million.
• Insiders, including Director Christopher Causey and COO Michael Benkowitz, have sold a combined 257,935 shares in recent months, indicating decrease in ownership among executives.
• Equities analysts have set new price targets for United Therapeutics, with Cantor Fitzgerald raising their target from $405 to $525, reflecting positive sentiment and an overall consensus rating of "Moderate Buy."

Galvin Gaustad & Stein LLC grew its position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 21.6% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 37,086 shares of the biotechnology company's stock after purchasing an additional 6,598 shares during the quarter. Galvin Gaustad & Stein LLC owned 0.08% of United Therapeutics worth $10,657,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. XTX Topco Ltd acquired a new position in shares of United Therapeutics during the 1st quarter valued at $313,000. Allianz Asset Management GmbH increased its position in shares of United Therapeutics by 96.9% during the 1st quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company's stock valued at $20,832,000 after purchasing an additional 33,254 shares during the period. LPL Financial LLC increased its position in shares of United Therapeutics by 77.3% during the 1st quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company's stock valued at $7,783,000 after purchasing an additional 11,007 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of United Therapeutics by 11.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock valued at $1,129,000 after purchasing an additional 376 shares during the period. Finally, Concurrent Investment Advisors LLC acquired a new position in shares of United Therapeutics during the 1st quarter valued at $227,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at United Therapeutics

In other United Therapeutics news, Director Christopher Causey sold 1,000 shares of the firm's stock in a transaction dated Wednesday, September 24th. The stock was sold at an average price of $440.00, for a total transaction of $440,000.00. Following the transaction, the director directly owned 4,865 shares in the company, valued at $2,140,600. This trade represents a 17.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of the firm's stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $450.24, for a total value of $10,130,400.00. The disclosure for this sale can be found here. Insiders have sold a total of 257,935 shares of company stock valued at $103,782,672 in the last three months. 10.30% of the stock is currently owned by insiders.

United Therapeutics Trading Down 0.8%

Shares of NASDAQ:UTHR opened at $445.38 on Friday. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $459.48. The business has a fifty day simple moving average of $369.35 and a 200 day simple moving average of $322.73. The firm has a market cap of $20.09 billion, a price-to-earnings ratio of 17.38, a P/E/G ratio of 6.84 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The firm had revenue of $798.60 million for the quarter, compared to analysts' expectations of $802.13 million. During the same quarter in the prior year, the business posted $5.85 earnings per share. United Therapeutics's revenue was up 11.7% on a year-over-year basis. On average, sell-side analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Cantor Fitzgerald lifted their price target on United Therapeutics from $405.00 to $525.00 and gave the company an "overweight" rating in a research report on Wednesday, September 10th. JPMorgan Chase & Co. reduced their price objective on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research note on Tuesday, July 8th. HC Wainwright raised their price objective on United Therapeutics from $400.00 to $500.00 and gave the stock a "buy" rating in a research note on Friday, September 5th. Weiss Ratings reissued a "hold (c+)" rating on shares of United Therapeutics in a research note on Wednesday. Finally, Morgan Stanley reduced their price objective on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research note on Thursday, July 10th. Ten analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $449.57.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.